Etbx-061 (Not yet branded)
Other Medications
Description
Etbx-061 is a multi-targeted recombinant adenovirus type 5 (Ad5) based cancer vaccine that targets three tumor-associated antigens: CEA (carcinoembryonic antigen), MUC1 (mucin 1), and brachyury. This immunotherapeutic agent is designed to stimulate the immune system to recognize and attack colorectal cancer cells expressing these specific antigens. The vaccine is part of combination immunotherapy regimens aimed at generating robust anti-tumor immune responses in patients with advanced colorectal cancer.
Mechanism of Action
Etbx-061 utilizes a replication-defective adenovirus vector to deliver genetic material encoding CEA, MUC1, and brachyury antigens directly to immune cells. Upon administration, the vaccine promotes the presentation of these tumor-associated antigens to T-cells, triggering both cellular and humoral immune responses. This multi-antigen approach aims to overcome tumor immune evasion by targeting multiple pathways simultaneously and reducing the likelihood of antigen loss variants.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 Estado EMA | Experimental |
 Acceso España | med_spain_not_available |
| Administration | Intramuscular |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.